This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEIAS05X_L.jpg
“We now expect organic sales growth between 8% and 8.5%. The underlying trading operating profit margin is expected around 17.0%. Underlying earnings per share in constant currency and capital efficiency are expected to increase,” it said after forecasting in October organic sales would rise around 8%.
Organic growth, which cuts out the impact of currency movements and acquisitions, was 8.5% in the nine months to the end of September, the highest since 2008.
Nestle also said it had decided to explore strategic options for peanut allergy treatment Palforzia “following slower than expected adoption by patients and healthcare professionals”. It expected the review to be completed in the first half of 2023.
